Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Multi Cap Fund median (32 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 26 Dec 2022 – 20 Aug 2026, limited by Union Multicap Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Union Multicap Fund | Nifty 500 |
|---|---|---|
| 26 Dec 2022 | ₹100.00 | ₹100.00 |
| 16 Apr 2023 | ₹100.00 | ₹99.39 |
| 05 Aug 2023 | ₹118.19 | ₹112.26 |
| 24 Nov 2023 | ₹127.85 | ₹117.26 |
| 14 Mar 2024 | ₹135.66 | ₹132.37 |
| 03 Jul 2024 | ₹162.80 | ₹151.88 |
| 23 Oct 2024 | ₹165.98 | ₹151.81 |
| 11 Feb 2025 | ₹150.36 | ₹139.24 |
| 02 Jun 2025 | ₹163.10 | ₹151.76 |
| 21 Sep 2025 | ₹173.28 | ₹156.10 |
| 10 Jan 2026 | ₹170.81 | ₹155.97 |
| 01 May 2026 | ₹171.94 | ₹150.76 |
| 20 Aug 2026 | ₹191.57 | ₹156.27 |
| Metric | Union · Direct NAV ₹18.64 Very High risk ★★★☆☆ | Category median Multi Cap Fund · 32 funds |
|---|---|---|
| +12.90% | +9.70% | |
| +17.36% | +16.81% | |
| — | +15.89% | |
| — | +15.33% | |
| +19.50% | +16.56% | |
| +16.29% | — | |
| +18.40% | +18.65% | |
| — | +16.76% | |
| — | +16.70% | |
| Risk | ||
| 15.04% | 14.82% | |
| 0.72 | 0.64 | |
| 0.97 | 0.87 | |
| -19.80% | -20.01% | |
| Nifty 500 | — | |
| +4.49% | +4.32% | |
| 0.95 | 1.01 | |
| 109.6% | 111.5% | |
| 88.2% | 92.7% | |
| 1.45% | 0.94% | |
| ₹1,340Cr | ₹3,392Cr | |
| 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹1.00K | — | |
| 111% | 57% | |
| Gaurav Chopra | — | |
| 26 Dec 2022 | — | |
| 75 | — | |
| 28.4% | — | |
| 2.6% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.